PJ Kelleher | LifeSci Advisors |
John Tucker | CEO |
Rachael Nokes | CFO |
Steve Parsons | SVP, Commercial |
Glen Santangelo | Jefferies |
Nik Gasic | SVB Securities |
Stacy Ku | Cowen |
Douglas Tsao | H.C. Wainwright |
Nazibur Rahman | Maxim Group |
Greetings | and welcome to the scPharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] As a reminder - this conference is being recorded. |
It is now my pleasure to introduce your host | PJ Kelleher - LifeSci Advisors. Thank you - Peter. PJ - you may begin. |
Thank you, operator.
Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements on this conference call, other than historical facts, are forward-looking statements within the meaning of the federal securities laws including, but not limited to statements regarding scPharmaceuticals' expected future financial results; and management's expectations and plans for the business and FUROSCIX.
The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are typically used to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain resins and uncertainties and other important factors that may affect business, financial condition and other operating results.